IMC Chicago
APLS

IMC Chicago’s Apellis Pharmaceuticals APLS Stock Holding History

IMC Chicago’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,200
Closed -$451K – 6328
2026
Q1 		$451K Sell
11,200
-36,800
-77% -$793K ﹤0.01% 4163
2025
Q4 		$1.21M Sell
48,000
-15,000
-24% -$352K ﹤0.01% 2832
2025
Q3 		$1.43M Buy
63,000
+22,200
+54% +$518K ﹤0.01% 2471
2025
Q2 		$706K Buy
40,800
+26,600
+187% +$492K ﹤0.01% 2676
2025
Q1 		$311K Sell
14,200
-38,000
-73% -$1.05M ﹤0.01% 2907
2024
Q4 		$1.67M Buy
52,200
+26,700
+105% +$803K ﹤0.01% 1999
2024
Q3 		$735K Buy
+25,500
New +$944K ﹤0.01% 2209
2023
Q4 		– Sell
-50,500
Closed -$1.92M – 1803
2023
Q3 		$1.92M Buy
+50,500
New +$2.22M ﹤0.01% 1002

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

IMC Chicago's APLS Position: Q2 2026 in Review

IMC Chicago sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 59,232 shares — an estimated $2.38M sold.

IMC Chicago first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $2.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • IMC Chicago reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 59,232 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
  • IMC Chicago first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • IMC Chicago's Apellis Pharmaceuticals position peaked at $2.38M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.